Want to see STOK full AI Analyst Report?
STOK Stock Chart & Stats
$29.30
$0.81(2.76%)
At close: 4:00 PM EDT
$29.30
$0.81(2.76%)
Day’s Range― - ―
52-Week Range$18.00 - $40.22
Previous CloseN/A
Volume36.19K
Average Volume (3M)885.20K
Market Cap
$2.07B
Enterprise Value$1.87K
Total Cash (Recent Filing)$292.82M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Nov 10, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.36
Shares Outstanding64,526,245
10 Day Avg. Volume538,018
30 Day Avg. Volume885,195
Financial Highlights & Ratios
PEG Ratio2.85
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$46.00Price Target Upside57.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.33
Revenue Forecast (FY)$25.72M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetMinimal-to-zero debt and sizable equity give Stoke durable financial flexibility to fund pivotal development, complete CMC/validation work, and absorb timing shifts. Low leverage reduces refinancing risk, supports strategic partnering, and preserves optionality ahead of potential approval years.
Phase III Enrollment Completed And Well-poweredFaster-than-expected enrollment, 0% discontinuations, and >90% powering materially raise the probability that the pivotal analysis will yield conclusive results. Durable enrollment and low dropout rates strengthen regulatory credibility and reduce statistical/execution risk heading into the multi-year approval pathway.
Robust Long-term OLE Efficacy And Safety DataMulti-year OLE data with statistically significant adaptive-function gains and durable seizure reductions, backed by NEJM publication, provide enduring clinical credibility. Such longitudinal evidence supports label claims, payer discussions, and physician confidence—critical advantages for a disease-modifying therapy in a rare neurology market.
Bears Say
TTM Cash Burn And Deteriorating ProfitabilityTrailing-twelve-months cash flow reverted to heavy burn and operating/net losses widened, increasing the probability Stoke will need incremental financing before commercialization. Persistent burn strains runway, can force dilutive raises, and may distract management from execution priorities over the next 2–6 months.
Regulatory/statistical Plan Unresolved With FDAKey SAP and hierarchy/composite choices for Vineland subdomains are still to be negotiated with FDA. Any misalignment could change the primary/secondary interpretation, limit label claims or require additional analyses, creating durable regulatory execution risk that can delay approval or narrow market access.
Runway And Ex-U.S. Access Contingent On Partner/milestonesCash and international commercialization plans depend in part on Biogen reimbursements, milestones and partner execution. Partner delays or missed payments would pressure funding and slow ex-U.S. launches, creating sustained operational and commercial risk beyond the U.S. timeline.
Stoke Therapeutics News
STOK FAQ
What was Stoke Therapeutics’s price range in the past 12 months?
Stoke Therapeutics lowest stock price was $18.00 and its highest was $40.22 in the past 12 months.
What is Stoke Therapeutics’s market cap?
Stoke Therapeutics’s market cap is $2.07B.
When is Stoke Therapeutics’s upcoming earnings report date?
Stoke Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 83 days.
How were Stoke Therapeutics’s earnings last quarter?
Stoke Therapeutics released its earnings results on Aug 03, 2026. The company reported -$0.93 earnings per share for the quarter, missing the consensus estimate of -$0.795 by -$0.135.
Is Stoke Therapeutics overvalued?
According to Wall Street analysts Stoke Therapeutics’s price is currently Undervalued.
Does Stoke Therapeutics pay dividends?
Stoke Therapeutics does not currently pay dividends.
What is Stoke Therapeutics’s EPS estimate?
Stoke Therapeutics’s EPS estimate is -0.92.
How many shares outstanding does Stoke Therapeutics have?
Stoke Therapeutics has 64,526,245 shares outstanding.
What happened to Stoke Therapeutics’s price movement after its last earnings report?
Stoke Therapeutics reported an EPS of -$0.93 in its last earnings report, missing expectations of -$0.795. Following the earnings report the stock price went up 7.138%.
Which hedge fund is a major shareholder of Stoke Therapeutics?
Currently, no hedge funds are holding shares in STOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.00 (57.00% Upside)
$46.00 (57.00% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 41.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.8%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
116.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.46%
Trailing 12-Months
Company Description
Stoke Therapeutics
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
STOK Company Deck
STOK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivers multiple strong operational and clinical positives: faster-than-expected Phase III enrollment (162 vs target ≥150), 0% discontinuations (vs 15% assumed), robust long-term OLE data (statistically significant Vineland improvements through 4 years, durable seizure reductions), completed manufacturing validation, and a pro forma cash position (~$420M) supporting runway to a potential early-2028 U.S. launch. Key risks are procedural and timing-related rather than clinical safety: SAP and label details are not yet finalized with the FDA, the final Phase III readout and completion of the rolling NDA extend into Q3 2027, inclusion of OLE data in the label is not guaranteed, and diagnosis/access gaps (particularly in adults) and reliance on partner execution outside North America remain challenges. On balance, the positive clinical progress, regulatory preparedness, financial runway, and commercial planning materially outweigh the remaining uncertainties.View all STOK earnings summariesSTOK Stock 12 Month Forecast
Average Price Target
$46.00
▲(57.00% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Xeris Pharmaceuticals
―
―
Rapport Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
27.38% Insiders
20.15% Mutual Funds
14.77% Other Institutional Investors
22.63% Public Companies and
Individual Investors